Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 11, 1996, Pages 2651-2654

  Robbins, Brian L ^a   Waibel, Brett H ^a   Fridland, Arnold ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ZIDOVUDINE; ZIDOVUDINE 5' PHOSPHATE; ZIDOVUDINE DERIVATIVE;

ARTICLE; CYTOTOXICITY; DRUG DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0029965606     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.11.2651     Document Type: Article

References (22)

1. Boucher, F. D., J. F. Modlin, S. Weller, A. Ruff, M. Mirochnick, S. Pelton, C. Wilfert, R. McKinney, Jr., M. J. Crain, M. M. Elkins, M. R. Blum, and C. G. Prober. 1993. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J. Pediatr. 122:137-144.
2. Fischl, M. A., C. B. Parker, C. Pettineli, M. Wulfsohn, M. S. Hirsch, A. C. Collier, D. Antoniskis, M. Ho, D. D. Richman, E. Fuchs, T. C. Merigan, R. C. Reichman, J. Gold, N. Steigbigel, G. S. Leoung, S. Rasheed, and A. Tsiatis. 1990. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 323:1009-1014.
3. Fischl, M. A., D. D. Richman, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, R. T. Schooley, G. G. Jasckson, D. T. Durack, and D. King. 1987. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 317:185-190.
4. Fridland, A., M. C. Connelly, and R. Ashmun. 1990. Relationship of deoxynucleotide changes to inhibition of DNA synthesis induced by the antiretroviral agent 3′-azido-3′-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CEM). Mol. Pharmacol. 37:665-670.
5. Furman, P. A., J. A. Fyfe, M. H. Sinclair, K. Weinhold, J. L. Rideout, G. A. Freeman, S. N. Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya, and D. W. Barry. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 83:8333-8337.
6. Ingrand, D., J. Weber, C. A. B. Boucher, C. Loveday, C. Robert, A. Hill, N. Cammack, and the Lamivudine European HIV Working Group. 1995. Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. AIDS 9:1323-1329.
7. Kline, M. W., L. M. Dunkle, J. A. Church, J. T. Goldsmith, A. T. Harris, M. E. Federici, M. E. Schultze, L. Woods, D. F. Loewen, S. Kaul, A. Cross, V. L. Rutkiewicz, H. M. Rosenblatt, I. C. Hanson, and W. T. Shearer. 1995. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 96:247-252.
8. Kuster, H., M. Vogt, B. Joos, V. Nadai, and R. Luthy. 1991. A method for the quantification of intracellular zidovudine nudeotides. J. Infect. Dis. 164:773-776.
9. Lambert, J. S., M. Seidlin, R. C. Reichman, C. S. Plank, M. Laverty, G. D. Morse, C. Knupp, C. McLaren, C. Pettinelli, F. T. Valentine, and R. Dolin. 1990. 2′,3′-Dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N. Engl. J. Med. 322:1333-1340.
10. Larder, B. A., S. D. Kerap, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
11. Meng, T. C., M. A. Fischl, and D. D. Richman. 1990. AIDS clinical trials group: phase I/II study of combination 2′, 3′-dideoxycytidine and zidovudine in patients with acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex. Am. J. Med. 88(Suppl. 5B):27S-30S.
12. Mitsuya, H. K., K. J. Weinhold, P. A. Furman, M. H. St. Clair, S. N. Lehrman, R. C. Gallo, D. Bolognesi, D. W. Barry, and S. Broder. 1985. 3′-Azido-3′-deoxythymidine (BWA A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 82:7096-7100.
13. Murphy, R. 1995. Clinical aspects of human immunodeficiency virus disease: clinical rationale for treatment. J. Infect. Dis. 171:S81-S87.
14. Robbins, B. L., J. Rodman, C. McDonald, R. V. Srinivas, P. M. Flynn, and A. Fridland. 1994. Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 38:115-121.
15. Sale, M., S. M. Sheiner, P. Volberding, and T. F. Blasche. 1993. Zidovudine response relationships in early human immunodeficiency virus infection. Clin. Pharmacol. Ther. 54:556-566.
16. Skowron, G., S. A. Bozzetle, L. Lim, C. B. Pettinelli, H. H. Schaumburg, J. Arezzo, M. A. Fischl, W. G. Powderly, D. J. Gocke, D. D. Richman, J. C. Pottage, Jr., D. Antoniskis, G. F. McKinley, N. E. Hyslop, Jr., G. Ray, G. Simon, N. Reed, M. L. Lofaro, R. B. Uttamchandani, L. D. Gelb, S. J. Sperber, R. L. Murphy, J. M. Leedom, M. H. Grieco, J. Zachary, M. S. Hirsch, S. A. Spector, J. Bigley, W. Soo, and T. C. Merigan. 1993. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann. Intern. Med. 118:321-330.
17. Slusher, J. T., S. K. Kuwahara, F. M. Hamazeh, L. D. Lewis, D. M. Kornhauser, and P. S. Lietman. 1992. Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure. Antimicrob. Agents Chemother. 36:2473-2477.
18. Sommadossi, J. P. 1995. Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2′,3′-dideoxynucleoside analogues. J. Infect. Dis. 171:888-892.
19. Tornevik, Y., B. Ullman, J. Baizarini, B. Wahren, and S. Eriksson. 1995. Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem. Pharmacol. 49:829-837.
20. Toyoshima, T., S. Kimura, S. Muramatsu, H. Takahagi, and K. Shimada. 1991. A sensitive non-isotopic method for the determination of intracellular azidothymidine 5′-mono, 5′-di- and 5′-triphosphate. Anal. Biochem. 196: 302-307.
21. Van Leeuwen, R., C. Katlama, V. Kitchen, C. A. B. Boucher, R. Tubiana, M. McBride, D. Ingrand, J. Weber, A. Hill, H. McDade, and S. A. Danner. 1995 Evaluation of safety and efficacy of 3TC (Lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J. Infect. Dis. 171:1166-1171.
22. Yarchoan, R., R. W. Klecker, K. J. Weinhold, P. D. Markham, H. K. Lyerly, D. T. Durack, E. Gelmann, S. N. Lehrman, R. M. Blum, D. W. Barry, G. M. Shearer, M. A. Fischl, H. Mitsuya, R. C. Gallo, J. M. Collins, D. P. Bolognesi, C. E. Myers, and S. Broder. 1986. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication to patients with AIDS or AIDS-related complex. Lancet i:575-580.